Scarica l'app Stockscreener
1.78
4.71%
0.08
Dopo l'orario di chiusura:
1.74
-0.04
-2.25%
Precedente Chiudi:
$1.70
Aprire:
$1.69
Volume 24 ore:
38,633
Relative Volume:
0.55
Capitalizzazione di mercato:
$4.93M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-11.00%
1M Prestazione:
+9.20%
6M Prestazione:
-84.08%
1 anno Prestazione:
-97.07%
Intervallo 1D:
$1.68
$1.78
Intervallo di 1 settimana:
$1.68
$2.0941
Portata 52W:
$1.52
$64.50
Autonomix Medical Inc Stock (AMIX) Company Profile
Nome
Autonomix Medical Inc
Settore
Industria
Telefono
832-277-7816
Indirizzo
21 WATERWAY AVENUE, SUITE 300, THE WOODLANDS
Confronta AMIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMIX
Autonomix Medical Inc
|
1.78 | 4.93M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Autonomix Medical Inc Borsa (AMIX) Ultime notizie
Ananda Pharma, Accsys Technologies, Autonomix Medical, BitwiseSmall Cap Week in Review - Proactive Investors
Autonomix Medical reports promising results in first-in-human trial for novel cancer pain therapy - Proactive financial news
Autonomix reports significant pain relief in cancer trial - Investing.com
Autonomix reports significant pain relief in cancer trial By Investing.com - Investing.com India
Autonomix Highlights Compelling Patient Testimonial Showing - GlobeNewswire
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-In-Human Proof-Of-Concept Trial in Pancreatic Cancer Pain - marketscreener.com
Mariner LLC Sells 11,756 Shares of Autonomix Medical, Inc. (NASDAQ:AMIX) - Defense World
It is Poised to be a Bull Market for Autonomix Medical Inc (AMIX) - Sete News
Autonomix Medical, Inc. Announces Successful Initial Trial Phase and Plans for Market Expansion Study in Pancreatic Cancer Pain Management - Nasdaq
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor 'What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - The Manila Times
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in - GlobeNewswire
Autonomix Medical Pain Treatment Trial Success Leads to Cancer Market Expansion | AMIX Stock News - Stock Titan
Autonomix Medical Inc (AMIX) Outlook: Looking Back For Insights - Stocksregister
Maxim Group Initiates Coverage on Autonomix Medical (NASDAQ:AMIX) - Defense World
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlo - GuruFocus
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic C - GuruFocus
How is AMIX’s stock performing after recent trades? - uspostnews.com
Autonomix Medical Inc (AMIX) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Autonomix provides update on initial phase on delivering transvascular energy - TipRanks
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic Cancer Pain Treatment | AMIX Stock News - GuruFocus
Autonomix advances pain treatment in cancer trials By Investing.com - Investing.com Australia
Autonomix advances pain treatment in cancer trials - Investing.com
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain - The Manila Times
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlook | AMIX Stock News - GuruFocus
Autonomix Medical, Inc. Reports Positive Outcomes in - GlobeNewswire
Revolutionary Cancer Pain Treatment Shows 100% Success Rate: Autonomix Medical's Breakthrough Trial Results - Stock Titan
Maxim Group Initiates Coverage of Autonomix Medical (AMIX) with Buy Recommendation - Nasdaq
Maxim Group Initiates Coverage on Autonomix Medical With Buy Rating, $5 Price Target - marketscreener.com
Autonomix Medical, Inc. to Present Innovative Neural Ablation Technology at EuroPCR 2025 - Nasdaq
Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR - GlobeNewswire
Revolutionary Neural Ablation Technology for Cancer Pain Management Showcased at Leading Medical Conference - Stock Titan
Autonomix Medical announces inducement grant - Medical Buyer
Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Autonomix Medical Expands Team with Strategic 5,000-Share Stock Option Grant to New Key Employee - Stock Titan
Autonomix Medical secures new European patent for nerve tech By Investing.com - Investing.com South Africa
Autonomix Medical Granted European Patent For Catheter-Based Neuromodulation Technology - Nasdaq
Autonomix Gains European Patent for Catheter-Based Tech - Medical Product Outsourcing
Autonomix Medical secures new European patent for nerve tech - Investing.com
Autonomix Medical Granted New European Patent For Proprietary Catheter-Based Technology - marketscreener.com
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology - GlobeNewswire
Medical Breakthrough: Autonomix's New EU Patent Powers Multi-Condition Treatment Platform - Stock Titan
Autonomix stock plunges to 52-week low of $1.52 amid steep annual decline - Investing.com Australia
Autonomix stock plunges to 52-week low of $1.52 amid steep annual decline By Investing.com - Investing.com South Africa
Analyzing Globus Medical (NYSE:GMED) & Autonomix Medical (NASDAQ:AMIX) - Defense World
Autonomix to begin U.S. clinical studies for FDA approval By Investing.com - Investing.com South Africa
Autonomix to begin U.S. clinical studies for FDA approval - Investing.com
Autonomix Medical, Inc. Engages Leading Medical Experts to - GlobeNewswire
Top Medical Experts Join Forces to Advance Revolutionary Pancreatic Cancer Pain Treatment - Stock Titan
Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO) - GlobeNewswire
Revolutionary Pancreatic Cancer Pain Treatment: Autonomix Medical Reveals First Clinical Results at ECIO 2025 - Stock Titan
Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Update - Defense World
Autonomix Medical Inc Azioni (AMIX) Dati Finanziari
Non sono disponibili dati finanziari per Autonomix Medical Inc (AMIX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):